Creatinine to Cystatin-C Ratio in Renal Cell Carcinoma: A Clinically Pragmatic Prognostic Factor and Sarcopenia Biomarker.

Low creatinine to cystatin-C ratio (Cr/Cys-C) may be a biomarker for low-muscle mass. Furthermore, low Cr/Cys-C is associated with decreased overall survival (OS), but to date, has not been examined in patients with renal cell carcinoma (RCC). Our objective is to evaluate associations between low Cr/Cys-C ratio and OS and recurrence-free survival (RFS) in patients with RCC treated with nephrectomy.

We performed a retrospective review of patients with RCC treated with nephrectomy. Patients with end-stage renal disease and less than 1-year follow up were excluded. Cr/Cys-C was dichotomized at the median for the cohort (low vs. high). OS and RFS for patients with high versus low Cr/Cys-C were estimated with the Kaplan-Meier method, and associations with the outcomes of interest were modeled using Cox proportional Hazards models. Associations between Cr/Cys-C and skeletal muscle mass were assessed with correlations and logistic regression.

A total of 255 patients were analyzed, with a median age of 64. Median (IQR) Cr/Cys-C was 1 (0.8-1.2). Low Cr/Cys-C was associated with age, female sex, Eastern Cooperative Oncology Group Performance Status ≥1, TNM stage, and tumor size. Kaplan-Meier and Cox regression analysis demonstrated an association between low Cr/Cys-C and decreased OS (HR = 2.97, 95%CI, 1.12-7.90, P =0.029) and RFS (HR = 3.31, 95%CI, 1.26-8.66, P = .015). Furthermore, a low Cr/Cys-C indicated a 2-3 increase in risk of radiographic sarcopenia.

Lower Cr/Cys-C is associated with inferior oncologic outcomes in RCC and, pending validation, may have utility as a serum biomarker for the presence of sarcopenia in patients with RCC treated with nephrectomy.

The oncologist. 2023 Aug 04 [Epub ahead of print]

Benjamin N Schmeusser, Henry Biermann, Edouard H Nicaise, Adil A Ali, Dattatraya H Patil, Eric Midenberg, Talia Helman, Manuel Armas-Phan, Reza Nabavizadeh, Shreyas S Joshi, Vikram M Narayan, Mehmet A Bilen, Sarah P Psutka, Kenneth Ogan, Viraj A Master

Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA., Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Department of Urology, University of Louisville, Louisville, KY, USA., Department of Urology, Mayo Clinic, Rochester, MN, USA., Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA., Department of Urology, University of Washington, Seattle, WA, USA.